Acquisition target has established proof of concept data demonstrating the therapeutic potential for the treatment of multiple solid tumors

Acquisition target已经建立了概念验证数据，证明了治疗多种实体瘤的治疗潜力

EDINBURGH, Scotland, May 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ('TC BioPharm' or the 'Company') (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors..

苏格兰爱丁堡，2024年5月6日/PRNewswire/-TC BioPharm（Holdings）PLC（“TC BioPharm”或“公司”）（纳斯达克：TCBP）是一家临床阶段的生物技术公司，开发用于癌症和其他适应症的异基因γδT细胞疗法平台，今天宣布执行一份不具约束力的意向书，以收购一家私营生物技术公司，该公司致力于开发用于治疗难治性癌症和实体瘤的创新嵌合抗原受体T细胞（CAR-T）疗法。。

This agreement is the second such agreement in as many months shows TCBP's commitment to its M&A strategy aimed at expanding its therapeutic platform.

该协议是数月来第二份此类协议，表明TCBP致力于其旨在扩大其治疗平台的并购战略。

CAR T-cell therapy modifies a patient's own immune cells to provide a heightened ability to identify and eliminate cancer cells.

CAR T细胞疗法可以改变患者自身的免疫细胞，从而提高识别和消除癌细胞的能力。

The target acquisition has developed a number of proprietary approaches to re-engineer CARs to better target solid tumors. The Company has generated pre-clinical proof of concept data that demonstrates the therapeutic potential of its lead CAR-T candidate for a range of solid tumors including colorectal, pancreatic, mesothelioma, ovarian and breast cancer.

target收购开发了许多专有方法来重新设计CAR以更好地靶向实体瘤。该公司已经产生了临床前概念验证数据，证明了其主要CAR-T候选物对一系列实体瘤的治疗潜力，包括结直肠癌，胰腺癌，间皮瘤，卵巢癌和乳腺癌。

In addition, the target acquisition is also developing a novel, allogeneic CAR-T for the treatment of autoimmune diseases..

此外，target acquisition还正在开发一种新型的同种异体CAR-T，用于治疗自身免疫性疾病。。

There can be no assurance that a definitive agreement will be executed or that the proposed transaction will be consummated on the terms or timeframe currently contemplated. Upon execution of the definitive agreements, the completion of the transaction will be subject to, among other matters, satisfaction of the conditions negotiated therein, the Company having secured adequate financing, and receipt of all third party (including governmental) approvals, licenses, consents, and clearances, as and when applicable..

无法保证将签署最终协议，也无法保证拟议交易将在目前预期的条款或时间范围内完成。在签署最终协议后，交易的完成将取决于其中谈判的条件的满足，公司已获得足够的融资，以及收到所有第三方（包括政府）的批准、许可、同意和许可（如适用）。。

'Management is extremely pleased to announce this second potential acquisiton which will provide strong advantages to our current therapeutic platform as well as expand our efforts into autoimmune disease,' said Mr. Bryan Kobel, CEO of TC BioPharm. 'There are substantial synergies between the two companies with extensive benefits to the business combination including CAR development expertise as well as gamma delta and alpha beta T-cells.

TC BioPharm首席执行官布莱恩·科贝尔（BryanKobel）说，管理层非常高兴宣布第二次潜在收购，这将为我们目前的治疗平台提供强大的优势，并将我们的努力扩展到自身免疫性疾病两家公司之间有着巨大的协同效应，对企业合并有着广泛的好处，包括汽车开发专业知识以及伽马三角洲和阿尔法-βT细胞。

Our existing expertise in gamma delta T-cells as well as transitioning processes and therapeutics from autologous to allogeneic will be impactful in advancing the solid tumor assets of the acquisition, the acquired company brings strong CAR engineering expertise to help us further develop our co-stimulatory CAR as well as a strong clinical team.

我们在γδT细胞方面的现有专业知识以及从自体到同种异体的过渡过程和治疗方法将对推进收购的实体瘤资产产生影响，被收购公司带来了强大的CAR工程专业知识，以帮助我们进一步开发共刺激CAR以及强大的临床团队。

We believe that the combination of these two companies provides a well balanced platform for investors and patients in our pursuit of creating next-generation cell therapies for the treatment of multiple indications. This represents not only multiple shots on goal, but an expanded asset base in several immune responder cells for the treatment of a wide range of disease with an extensive patent portfolio.

我们相信，这两家公司的联合为投资者和患者提供了一个平衡的平台，以创造用于治疗多种适应症的下一代细胞疗法。这不仅代表了多次射门，而且代表了几个免疫应答细胞的扩大资产基础，用于治疗各种疾病，拥有广泛的专利组合。

As such, 2024 and 2025 could now have inflections points for data in several pipeline assets in a variety of indications. I am proud of our ability to navigate a difficult capital market environment and identify complimentary resources that will continue to enhance the overall value of our company and look forward to working with our expanded team.'.

因此，2024年和2025年可能会出现各种迹象中多个管道资产数据的拐点。我为我们有能力驾驭困难的资本市场环境和确定互补资源而感到骄傲，这些资源将继续提高我们公司的整体价值，并期待着与我们扩大的团队合作。”。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to effect any budget savings or execute on any M&A or capital raising strategy.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明。本报告表8-K中包含的所有与历史事实无关的报表均应视为前瞻性报表，包括但不限于有关公司意图或能力节省预算或执行任何并购或筹资战略的报表。

These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

这些报表基于管理层当前的假设，既不是承诺也不是保证，但涉及已知和未知的风险、不确定性和其他重要因素，这些因素可能导致公司的实际业绩、业绩或成就与前瞻性报表明示或暗示的任何未来业绩、业绩或成就存在重大差异。

For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov.

有关可能导致实际结果与本8-K表当前报告中的前瞻性陈述存在重大差异的其他重要因素，请参阅我们截至2023年12月31日的10-K表年度报告中“风险因素”标题下确定的风险和不确定性，以及我们向SEC提交的其他报告，所有这些报告均可在公司投资者关系网站www.tcbiopharm.com和SEC网站www.SEC.gov上找到。

All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances..

所有前瞻性陈述仅反映截至本报告8-K表之日公司的信念和假设。公司没有义务更新前瞻性陈述以反映未来事件或情况。。

About TC BioPharm (Holdings) PLC

关于TC BioPharm（Holdings）PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue..

TC BioPharm是一家临床阶段的生物制药公司，专注于γδT细胞疗法的发现，开发和商业化，用于治疗癌症，并具有急性髓细胞白血病的人类疗效数据。γδT细胞是天然存在的免疫细胞，它体现了先天性和适应性免疫系统的特性，并且可以从本质上区分健康和患病组织。。

TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide..

TC BioPharm是开发γδT细胞疗法的领导者，也是第一家在肿瘤学中进行II期/关键临床研究的公司。该公司正在进行两项由研究者发起的临床试验，用于其未经修饰的γδT细胞产品系-OmnImmune®治疗急性骨髓性白血病的2b/3期关键试验，使用该公司专有的同种异体CryoTC技术为全球诊所提供冷冻产品。。

View original content to download multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-execution-of-second-non-binding-letter-of-intent-for-acquisition-targeting-innovative-car-t-therapies-302136232.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/tc-biopharm-announces-execution-of-second-non-binding-letter-of-intent-for-acquisition-targeting-innovative-car-t-therapies-302136232.html

SOURCE TC BioPharm

来源TC BioPharm

Company Codes: NASDAQ-NMS:TCBP

公司代码：NASDAQ-NMS：TCBP